Validation of myelin imaging technique in patients with MS

A study recently published in Annals of Neurology determined that SyMRI provides robust myelin quantification in patients with MS.

The study published by Ouellette et al. concluded that SyMRI “provides robust myelin quantification that detects diffuse demyelination in normal-appearing tissue in multiple sclerosis, which is associated with both cognitive and clinical disability. Since the technique is fast with automatic post‐processing and FDA/CE clinical approval, it can be a clinically feasible biomarker that may be suitable to monitor myelin dynamics and evaluate treatments aiming at remyelination.”

The study from the Karolinska Institute titled ‘Validation of rapid magnetic resonance myelin imaging in multiple sclerosis’ from A Ouellette et al. was published in the Annals of Neurology.

The aim of the study was to assess the specificity, robustness and clinical value of the myelin quantification in SyMRI. This was done both ex-vivo, using three MS brain samples with various staining techniques, as well as in-vivo on 71 MS patients and 21 healthy controls.

Myelin segmentation using SyMRI correlated with myelin-related stains with good precision, providing further validation of the technique.

To learn more, contact Hege Nåbo at +46 073272421 or hege.nabo@syntheticmr.com

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from one 6-minute scan. The SyMRI product is available in different packagers. SyMRI IMAGE provides fast MRI workflows, allowing high-patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI is a CE-marked and FDA 510(k) cleared product. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden.